Update on propranolol for infantile hemangioma: Where are we now?

Amanda A. Cyrulnik, Sharon A. Glick

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

The discovery of propranolol for the treatment of infantile hemangioma in 2008 has revolutionized management of this condition. Hundreds of reports have corroborated the initial published findings that propranolol is a safe and efficacious therapeutic agent. Furthermore, it is well tolerated in infants and can markedly alter the natural history and potential disfigurement of these lesions. The goal of this review is to outline the salient features of infantile hemangioma and the optimal use of propranolol as a first-line treatment modality.

Original languageEnglish (US)
Pages (from-to)e16-e25
JournalNeoReviews
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Update on propranolol for infantile hemangioma: Where are we now?'. Together they form a unique fingerprint.

  • Cite this